

40 YEARS of collaboration, innovation and education.



CAPA using Monte Carlo

Joern Meissner, Managing Director / CEO Meissner Consulting GmbH, Germany



V2.2

CAPA using Monte Carlo



- Josef Mittendorfer, High Tech Consulting, Austria
- Byron J. Lambert and Vu H. Le, Abbott Vascular, USA
- Dharmendra Patel, Abbot Diabetes Care, UK
- Joern Meissner, Meissner Consulting, Germany

Contact: <u>meissner@meissner-consulting.com</u>



CAPA using Monte Carlo



<u>Corrective Action / Preventive Action:</u>

 Organizational process improvement, based on the systematic investigation of root causes of identified problems to attempt to prevent their reoccurrence (corrective action) or prevent occurrence (preventive action)

Monte Carlo Modeling

- using randomness to solve problems that might be deterministic in principle
- Large number of events, CPU time
- Geometry modeling and beam source modeling used to be user-time intensive



Why Modelling?



Packaging Planning

- Minor differences and movement inside the packaging
- Shadow effects by variations
- Packaging optimization
- Material change effects on dose
- → Qualitative and Quantitative Analysis
 → Reduce Risk

Medical Product Design

- Include sterilization early in the design
- Combination Products
- Electronic Components (10-500Gy)
- Complex Shadow effects
- ➔ Define energy range
- ➔ Design for radiation sensitive areas within the product
- → Save development time

Why Modelling?



CAPA

- Compare PQ data with Simulation
- Simulate many more dosimeters
 - Non-measurable locations
- Define & vary Critical Control Points Motion in packaging, materials, orientation, beam faults, MAD locations, min dose locations, product as dosimeter,...
- ➔ Really understand Complexity
- ➔ Reduce Risk & Time
- ➔ Predict & Prevent

Prototyping


- custom implants
- 3D-printed parts
- Create / avoid shadow regions
- Benchmark simulated product
- Use simulated dose map

Sterilize Parts that exist only once
 Enable Conforming Process

IMRP2016 | VANCOUVER bc, canada Our Tool



- Create geometry within tool proprietary 3D CAD
- Import 3D files from other sources and modify in GUI
- Simulate Dosimeters
 - Measurable locations (PQ)
 - Non-measurable locations
 - Parts of product as dosimeter
- ➔ Simplify Setup and Variations
- → Save User Time










Project Specific Benchmarking Example







Simulation (5 ° Resolution)






Tube: 2mm wall thickness, 4cm radius Material: PC

0° Direction

Dosimeter: Water with 5° resolution Single Sided Irradiation




Project Specific Benchmarking Example



PC Tube: d=40mm d=2mm

Dosimeter: CTA-Strip d=125µm 1° Resolution

Work-In-Progress



IMRP2016 | VANCOUVER bc, canada








- Sterilization of Cardiovascular Stents
- Compliance Card must be inside the package
- Influence on Sterilization Dose Distribution
 - When parts (Compliance Card) inside the packaging move?
 - When the orientation of a stent package is different?




IQ and OQ setup - Benchmarking






Cardiovascular Stent Package





Stent modeling in the GUI






IMRP2016 | VANCOUVER bc, canada




Compliance Card Moving



Compliance Card in Center




Variation of Position





Compliance Card Moving






Beam Direction — Reference Dose Monitoring •

Compliance Card - Baseline Scenario

IMRP2016



Reference Dose: 23.6 kGy

MEISSNEI

- ± 2.2% 5% at 1σ
- ~ 6hrs on high performance workstation

Scenario


VANCOUVER


BC. CANADA

All compliance cards shadow locations E,F,I



Compliance Card - Scenario Variation





Scenario

All compliance cards shadow locations E,F,I


Except package 4, 5 and 6

First results – still Work-In-Progress

- Multi-parameter
 - We would have predicted an change for locations E,F and I
 - We saw a change at location H
 - Due to multi stentpackage, 45°
- Simulations provide
 - input for verification/benchmarking scenarios
 - Trends
 - Ideas for more critical control points (→prevent)

IMRP2016


VANCOUVER




Orientation Defects



Standard Orientation




Variations, unit 1, 8 and 15







Orientation Defects - Scenario Variation



First results – still Work-In-Progress



- Overall dose distribution homogeneous for each location; within statistical uncertainties
- Worst case defect: Front-Bottom
- Manageable defects
- Preventive Action
 - \rightarrow Reset range slightly for $D_{min}/D_{ref} D_{max}/D_{ref}$

IMRP2016

Conclusions - CAPA



- Today we presented a Method and a Tool
 - 3D geometry input, easy adaptation, quick to add complexity
- The results shown today are very preliminary, but
 - Demonstrate the Effectiveness for Variance Analysis
 - Provide additional data to Support Defect Resolution
 - Help identify cases where Corrective Actions are likely required
 - Help set limits for Preventive Actions
- Performance Qualification Benchmarking
 - Verify measurable locations, determine uncertainties
 - Trust non-measurable locations



Conclusions - Business



- Understand complexity
 - Gain Predictability
 - Reduce Risk
- Simulate vs. Experiment
 - Many more dose maps than one would perform experimentally
 - Much less resource use (people, beam time, preparation time, travel, analysis)
 - Reduced development time and cost
- 3D interface to Monte Carlo
 - Quick Iterations: Maintain focus of development team
 - Allow to quickly increase complexity



THANK YOU!